Phase 3 Trial Testing Aromasin-Chidamide Combo for Advanced Breast Cancer Meets Primary Goal

Phase 3 Trial Testing Aromasin-Chidamide Combo for Advanced Breast Cancer Meets Primary Goal
Adding investigational therapy chidamide to Aromasin (exemestane) significantly delayed disease progression or death in patients with advanced breast cancer, results from a Phase 3 trial show. This means that the pivotal trial (NCT02482753) has met its primary goal of progression-free survival, while maintaining a manageable safety profile, Chipscreen Biosciences recently announced. This is the first trial demonstrating the beneficial effects of Aromasin and chidamide in hormone receptor (HR)-positive advanced breast cancer patients who had failed prior hormone therapy. Chidamide, developed by China-based Chipscreen, is an inhibitor of histone deacetylase (HDAC) enzymes with a better tolerability profile than other HDAC inhibitors. The medicine prevents the growth, proliferation, and transformation of cancer cells, and induces anti-cancer immune responses. It is being evaluated in multiple clinical trials, either alone or in combination with other therapies, as a potential treatment for several blood and solid cancers. This randomized, double-blind, placebo-controlled Phase 3 trial was designed to evaluate the safety and effectiveness of chidamide in combination with Aromasin in postmenopau
Subscribe or to access all post and page content.